Company press releases
| Tid | Selskap | Tittel | Sektor | Kategori |
|---|---|---|---|---|
| 18 Nov 2025 07:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma Q3 2025: Promising Results Accelerating Development Strategy | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 14 Nov 2025 07:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to Q3 2025 Results Presentation | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 11 Nov 2025 07:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma kunngjør lovende interimdata fra NeoLIPA-studien ved Radiumhospitalet | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 11 Nov 2025 07:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma Announces Promising Interim Data on Neoadjuvant Treatment of Melanoma with Ruxotemitide from the NeoLIPA Study at the Norwegian Radium Hospital | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 Nov 2025 07:00 CET |
LYTIX BIOPHARMA AS | New Phase II Study Data from Lytix Biopharma’s Partner Presented at SITC 2025 Further Validate Unique Immune-Activating Mechanism of Ruxotemitide | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 10 Oct 2025 11:46 CEST |
LYTIX BIOPHARMA AS | Finansiell kalender | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 10 Oct 2025 11:46 CEST |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 08 Oct 2025 07:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma’s licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 01 Sep 2025 19:51 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Grant of share options to management and key personnel | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 28 Aug 2025 07:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma Q2/H1 2025: Preparing for a milestone-rich second half with advancing clinical programs and strengthened organization | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 21 Aug 2025 13:53 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to Q2 2025 Results Presentation | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 21 May 2025 16:05 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: GRANT OF SHARE OPTIONS | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 15 May 2025 07:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma Q1 2025: Strong clinical momentum supports a clear path to Phase III and broader pipeline progress | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 09 May 2025 07:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to Q1 2025 Results Presentation | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 29 Apr 2025 14:19 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Minutes from Ordinary General Meeting and Election of New Board of Directors | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 22 Apr 2025 21:18 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Recommendation from the Nomination and Compensation Committee to the Annual General Meeting, resignation by board Chair | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 10 Apr 2025 07:10 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Notice of Annual General Meeting on 29 April 2025 | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 10 Apr 2025 07:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Annual Report for 2024 | 20103010 Biotechnology | Årsrapporter og revisjonsberetninger |
| 13 Feb 2025 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma Q4 2024: Solid clinical results strengthen the path to Phase III and further advancements in 2025 | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 12 Feb 2025 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma receives Notice of Allowance for U.S. patent application covering its LTX-315 clinical program | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 07 Feb 2025 08:56 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to Q4 2024 Results Presentation | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 22 Jan 2025 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS – Licensing partner Verrica Pharmaceuticals presents clinical data with LTX-315 at the 2025 Winter Clinical Dermatology Conference | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 15 Jan 2025 13:05 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS - New share capital registered | 20103010 Biotechnology | Kapital- og stemmerettsendringer |
| 07 Jan 2025 19:12 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS - Cancellation of Subsequent Offering | 20103010 Biotechnology | Innsideinformasjon |
| 02 Jan 2025 11:45 CET |
LYTIX BIOPHARMA AS | Finansiell kalender | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 02 Jan 2025 11:45 CET |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Dec 2024 17:24 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS - Mandatory Notification of Trade – Redelivery of Lent Shares to Closely Associated Party of a Primary Insider | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 23 Dec 2024 17:03 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS - New share capital registered | 20103010 Biotechnology | Kapital- og stemmerettsendringer |
| 17 Dec 2024 15:53 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS - Mandatory Notification of Trade - Share Lending by Closely Associated Party of a Primary Insider | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 17 Dec 2024 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates | 20103010 Biotechnology | Meldepliktig handel for primærinnsidere |
| 17 Dec 2024 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Key information relating to potential subsequent offering | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 17 Dec 2024 00:27 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed | 20103010 Biotechnology | Innsideinformasjon |
| 16 Dec 2024 16:45 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma – Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement | 20103010 Biotechnology | Non-regulatory press releases |
| 16 Dec 2024 16:45 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma – Lytix lanserer emisjon for småinvestorer via PrimaryBid og Nordnet, parallelt med en rettet emisjon | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 16 Dec 2024 16:32 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid | 20103010 Biotechnology | Innsideinformasjon |
| 26 Nov 2024 12:54 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma presents updated phase II results from skin cancer study (BCC) at the DNB Nordic Healthcare Conference | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 21 Nov 2024 15:40 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma – Licensing partner Verrica Pharmaceuticals announces the pricing of a underwritten public offering, raising approximately USD 42 million upon completion | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 19 Nov 2024 07:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 12 Nov 2024 10:10 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to Q3 2024 Results Presentation | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 06 Nov 2024 13:34 CET |
LYTIX BIOPHARMA AS | First patient treated in new phase II clinical trial at Radiumhospitalet in Oslo – promising use of Lytix cancer treatment in patients with early-stage melanoma | 20103010 Biotechnology | Non-regulatory press releases |
| 06 Nov 2024 13:34 CET |
LYTIX BIOPHARMA AS | Lovende fase II-studie i pasienter med tidligfase føflekkreft startet opp ved Radiumhospitalet - første pasient behandlet med Lytix’ kreftbehandling | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 05 Nov 2024 07:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma – Oppdatering fra lisensieringspartner Verrica Pharmaceuticals | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 05 Nov 2024 07:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma - Update from licensing partner Verrica Pharmaceuticals | 20103010 Biotechnology | Non-regulatory press releases |
| 01 Nov 2024 07:04 CET |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 01 Nov 2024 07:04 CET |
LYTIX BIOPHARMA AS | Finansiell kalender | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 24 Oct 2024 14:11 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma Highlights Positive Data on LTX-315 in Collaboration with Verrica Pharmaceuticals at 2024 Fall Clinical Dermatology Conference | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 29 Aug 2024 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 23 Aug 2024 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to Q2 2024 Results Presentation | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 14 Aug 2024 13:37 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Phase II preliminary results from skin cancer (BCC) clinical trial show an 86 percent overall reduction of tumor size, complete clearance in half of the patients and the potential to be utilized as a first-line therapy | 20103010 Biotechnology | Innsideinformasjon |
| 14 Aug 2024 13:37 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma: Foreløpige hovedresultater fra fase II-studie i pasienter med hudkrefttypen basalcellekarsinom viser 86 % total reduksjon i svulststørrelse, fullstendig fjerning av svulstene i halvparten av pasientene og potensial som førstelinjeterapi | 20103010 Biotechnology | Inside information |